Pharmaceutical composition for treatment of eye diseases comprising retinal organoid-derived exosomes

Abstract

A pharmaceutical composition and a food composition for the prevention or treatment of degenerative retinal diseases, corneal epithelium wounds, and dry eye syndrome, comprising retinal organoid-derived exosomes is disclosed. The exosomes can include at least one miRNA selected from the group consisting of hsa-miR-122-5p, hsa-miR-3591-3p, hsa-miR-99a-5p, hsa-miR-148a-3p, hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7f-5p, hsa-miR-125a-5p, hsa-miR-100-5p, hsa-miR-4443, hsa-miR-26a-5p, hsa-miR-128-3p, hsa-miR-27b-3p, hsa-miR-126-3p, hsa-miR-10a-5p, hsa-miR-99b-5p, hsa-let-7e-5p, hsa-miR-21-5p and hsa-miR-30d-5p.

Dependencies are inferred from the claim text.